DGX

Quest Diagnostics Inc Health Care Services-Medical Laboratories S&P 500Russell 3000

$251.82Close $40.8BMarket cap $171.25 – $252.9252-week range Late-januaryNext report · estimated

Stage 2 Leader 62nd of 68

Highlights

Strengths

In a stage-2 uptrend all 8 trend conditions pass
Leading the market RS 82 · stronger than 82% of stocks over 12 months
RS line at a 1-year high outperforming the S&P 500 more than at any point this year
Near its high at its 52-week high
Earnings growing EPS +28% year on year, faster than the quarter before (+14 pts)

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Oct 23, 2026

Off 12-month high 0%

1wk 4.1% price change

1mo 8.4% price change

12-month return 45% market up 11% · its own up 35%

F-score 6 / 9 Mixed

Altman Z″ 3.52 Low risk

P/E 41.1× price / earnings

PEG 2.96 P/E / EPS growth

P/B 5.7× price / book

Earnings yield 3.4% EBIT / enterprise value

Cheaper than 44% of the market · around average

Revenue growth 12% year on year

EPS growth 28% latest quarter · +14 pts

Sales growth 10% latest quarter · -0 pts

ROE 14% return on equity

Free cash margin 12% $1.4B FCF

D/E 0.72 long-term debt / equity

Net debt / EBITDA 2.2×

Interest cover 5.9×EBIT / interest

Piotroski tests

profitability slipped from last year
short-term liquidity weakened
assets working less efficiently
profitable on its assets
generating cash from operations
profits backed by cash
reduced long-term debt
no new shares issued
gross margin widened

Repair signals

Long-term debt down 8% ($5.6B → $5.2B)

Trade setup

ATR% 2.5% $6.36 a day · 2×ATR $239.09

RS 82 / 99 vs the universe

Trend 8 / 8 trend template

Relative volume 0.9× vs 50-day average

Up/down volume 0.86 50 sessions

Implied move — no scheduled report

Trend template · 8 of 8

Screen verdict

1 of 3 screens

Stage 2 Leader in mixed conditions
- RS 82
- Trend 8/8
- Off 12-month high 0%
- EPS growth +28% (accel +14 pts)
- Sales growth +10% (accel -0 pts)
- Altman Z″ 3.52 (low risk)

Warning signs

none flagged

No restatement or impairment
Equity positive
Interest covered
No material dilution
Profits tracking cash
Margins and revenue not shrinking

Last reported Oct 22, 2026

Results reaction Oct 22, 2026+3% vs market2 sessions after results

Options $223,22826.6% IV · activity

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $11.0B +12% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $992.0M +14% on FY2024

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $1.4B +50% on FY2024

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Gross 33%
Net 9%
Free cash 12%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $4.7B net debt

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 162m -25.3% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$9.4B	$10.8B	$9.9B	$9.3B	$9.9B	$11.0B
Gross margin	38%	39%	35%	33%	33%	33%
Operating income	$2.0B	$2.4B	$1.4B	$1.3B	$1.3B	$1.6B
Net income	$1.4B	$2.0B	$946.0M	$854.0M	$871.0M	$992.0M
Net margin	15%	18%	10%	9%	9%	9%
Earnings per share	$10.52	$15.59	$8.02	$7.56	$7.71	$8.78
Free cash flow	$1.6B	$1.8B	$1.3B	$864.0M	$909.0M	$1.4B
Free cash margin	17%	17%	13%	9%	9%	12%
Cash	$1.2B	$872.0M	$315.0M	$686.0M	$549.0M	$420.0M
Long-term debt	$4.0B	$4.0B	$4.0B	$4.4B	$5.6B	$5.2B
Shareholders' equity	$6.8B	$6.4B	$5.9B	$6.3B	$6.8B	$7.2B
Shares outstanding	217m	162m	162m	162m	162m	162m

What options price now

Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology: $239 – $265 ±5.3% by Nov 20, 2026
Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology: Bigger 26.6% priced · 19.7% recent
Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology: About the same
Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology: past week: costs less

Positioning

Premium traded: $223,228 calls $59,212 · puts $164,015 · latest session
Puts against calls, by premium Money spent on puts divided by money spent on calls. Measured in dollars rather than contracts on purpose: counting contracts treats a hundred cheap lottery tickets as more meaningful than one large position, which is backwards. Methodology: 2.77× +1.78 over the week
Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology: calls +464 · puts +1.74k past week

For options traders: ATM IV 26.6% (+1.9% 1w) · 1m ÷ 3m IV 1.00 · 25Δ skew 0.1 pts · Net GEX $1.5M

Most traded contracts

No contract passed the liquidity filters this week.

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Oct 23, 2026	Quarterly ↗	Sep 30, 2026	23d
Jul 23, 2026	Quarterly ↗	Jun 30, 2026	23d
Apr 22, 2026	Quarterly ↗	Mar 31, 2026	22d
Feb 26, 2026	Annual ↗	Dec 31, 2025	57d
Oct 21, 2025	Quarterly ↗	Sep 30, 2025	21d
Jul 23, 2025	Quarterly ↗	Jun 30, 2025	23d
Apr 23, 2025	Quarterly ↗	Mar 31, 2025	23d
Feb 20, 2025	Annual ↗	Dec 31, 2024	51d
Oct 23, 2024	Quarterly ↗	Sep 30, 2024	23d
Jul 24, 2024	Quarterly ↗	Jun 30, 2024	24d
Apr 24, 2024	Quarterly ↗	Mar 31, 2024	24d
Feb 22, 2024	Annual ↗	Dec 31, 2023	53d

Current reports

Filed	Disclosed
Oct 22, 2026	Results ↗
Oct 22, 2026	Other events ↗
Oct 6, 2026	Director or officer change ↗
Jul 23, 2026	Results ↗
May 21, 2026	Shareholder vote ↗
May 8, 2026	Material agreement ↗
May 1, 2026	Other events ↗
Apr 21, 2026	Results ↗
Mar 12, 2026	Director or officer change · Regulation FD ↗
Feb 10, 2026	Results · Other events ↗
Jan 12, 2026	Results · Regulation FD ↗
Oct 21, 2025	Results ↗